Oncotelic Therapeutics Inc. OTLC Archives

ThursdayApr 16, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech Through AI-Robotics Pivot, Unlocking New Value in GMP Automation

Oncotelic Therapeutics has recently entered a strategic partnership with TechForce Robotics to commercialize a PDAOAI-enhanced, GMP-compliant robotics platform The collaboration integrates AI-driven compliance systems with advanced robotics for pharmaceutical manufacturing automation This pivot underscores a broader strategy: extending Oncotelic’s AI capabilities beyond therapeutics into scalable, high-value industrial applications Oncotelic Therapeutics (OTCQB: OTLC) is signaling a significant strategic evolution, moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation,…

FridayApr 10, 2026 9:20 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In AINewsWire Editorial On AI-Driven Pharma Manufacturing

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in an editorial published by AINewsWire, part of the Dynamic Brand Portfolio at IBN (InvestorBrandNetwork), highlighting the growing role of artificial intelligence in pharmaceutical manufacturing. The editorial underscores a sector-wide shift toward integrating AI directly into production workflows as a continuous compliance layer, enabling real-time monitoring, validation and optimization of processes to meet evolving Good Manufacturing Practice requirements, while positioning companies like Oncotelic at the intersection of biotechnology and advanced digital systems driving scalable efficiency and long-term cost advantages. To view the full press release, visit https://ibn.fm/S3jjv About Oncotelic Therapeutics Oncotelic Therapeutics, Inc. is…

WednesdayApr 08, 2026 9:45 am

From Big Data to Better Drugs: How AI-Driven Platforms Are Changing Cancer Research

Cancer research often relies on massive and complex datasets, which can take time and effort to sift through manually. The proprietary PDAOAI platform from Oncotelic Therapeutics helps with this problem as it was designed to analyze large biomedical datasets to extract meaningful signals and help researchers. The company has also curated a detailed TGF-β literature corpus containing 125,000+ PubMed abstracts that represents all of the scientific knowledge related to TGF-β. This has now expanded to >20M abstracts representing the totality of scientific literature. Cancer research is crucial for understanding, diagnosing, treating, and preventing the disease. However, this research often relies…

ThursdayApr 02, 2026 9:50 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Partners with TechForce Robotics to Advance AI-Enabled GMP Automation Platform

Oncotelic Therapeutics (OTCQB: OTLC) announced a strategic partnership with TechForce Robotics to advance commercialization of its PDAOAI-enabled, GMP-compliant robotics platform designed for pharmaceutical manufacturing and regulated environments. The integrated system combines Oncotelic’s proprietary AI capabilities with TechForce’s robotics and manufacturing expertise to enable automated material handling, real-time monitoring and compliance workflows, with scalability for broader deployment, as the companies move forward under a joint development, manufacturing and licensing agreement to address growing demand for intelligent, compliant automation solutions. To view the full press release, visit https://ibn.fm/nvCXn About Oncotelic Therapeutics Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development…

TuesdayMar 24, 2026 9:30 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) To Present Deciparticle Platform And Pipeline At BIO-Europe Spring 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present its Deciparticle (TM) nanomedicine platform and clinical pipeline at BIO-Europe Spring 2026 on March 25, where it has been selected as a presenting company. The company will highlight its next-generation drug delivery technology along with two lead candidates, Sapu003 (Everolimus for Injection), currently in Phase 1 trials, and Sapu006 (Docetaxel for Injection), entering Phase 1, as it seeks strategic partnerships to advance development and commercialization. To view the full press release, visit https://ibn.fm/Slq47 About Sapu Nano Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug…

MondayMar 23, 2026 9:40 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Subsidiary Sapu Nano To Present Everolimus Toxicology Data At SOT 2026

Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego, highlighting findings on tissue concentration–driven effects and organ-specific outcomes beyond traditional plasma pharmacokinetics. The presentation underscores the importance of tissue-level drug distribution in determining toxicity profiles and supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations. To view the full press release, visit https://ibn.fm/kZzE3 About Sapu Nano Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical…

MondayFeb 23, 2026 9:40 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In NetworkNewsAudio On Biotech M&A Trends

Oncotelic Therapeutics (OTCQB: OTLC) is featured in a NetworkNewsAudio Audio Press Release titled “Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A,” highlighting growing investor interest in clinical-stage platforms supported by existing human data. The editorial notes that programs demonstrating clinical activity offer clearer valuation benchmarks and reduced uncertainty compared with preclinical assets, positioning companies with diversified clinical pipelines, including oncology and CNS-focused targets such as TGF-β signaling and delivery-based approaches, to align with industry demand for validated mechanisms and strategic portfolio depth. To view the full press release, visit https://ibn.fm/cZmVn About Oncotelic Therapeutics Inc. Oncotelic Therapeutics…

FridayFeb 20, 2026 10:40 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS and Oncology Momentum

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in an editorial published by BioMedWire, one of more than 75 brands within the InvestorBrandNetwork. The article, titled “Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development,” highlights growing pharmaceutical interest in clinical-stage assets supported by human data and features Oncotelic as an example of a diversified clinical-stage company. The editorial notes the company’s recently expanded international intellectual property coverage for OT-101, its proprietary TGF-β antisense therapeutic platform, strengthening protection across neurology, oncology and CNS drug-delivery technologies designed to cross the blood–brain barrier. To view the full press release, visit https://ibn.fm/2SuJ3…

WednesdayFeb 18, 2026 9:30 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Late-Stage Biotech M&A Trends

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in an editorial published by BioMedWire, one of more than 75 brands within the Dynamic Brand Portfolio at IBN (InvestorBrandNetwork), highlighting the growing focus in biotech mergers and acquisitions on de-risked, late-stage assets with clinical validation. The article, titled “Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A,” examines how pharmaceutical companies and investors are prioritizing programs with established safety and efficacy data, placing companies such as Oncotelic, with multiple clinical- and late-stage oncology and central nervous system programs, in alignment with current M&A trends as it advances its…

WednesdayJan 21, 2026 1:36 pm

QualityStocksNewsBreaks – Oncotelic Therapeutics Inc.’s (OTLC) Deciparticle(TM) Platform Expands Possibilities in Immunology and Oncology

Oncotelic Therapeutics (OTCQB: OTLC) is rapidly emerging in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. “Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new data at the 2025 San Antonio Breast Cancer Symposium (‘SABCS’), highlighting that its Deciparticle(TM) platform can package even the toughest, water-resistant drugs into smaller, uniform nanoparticles that are small enough for effective and safe intravenous use,” reads a recent article. “The platform shows high-level compatibility across different therapeutic categories. All five main macrolide mTOR inhibitors, including temsirolimus, sirolimus, ridaforolimus, Everolimus (Afinitor(R)), and umirolimus, formed stable,…

Site Search

Company Search

Tag: Oncotelic Therapeutics Inc. OTLC